Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis

References

• JostinsLRipkeSWeersmaRKHost-microbe interactions have shaped the genetic architecture of inflammatory bowel diseaseNature2012491742211912423128233
   PubMed Web of Science ®Google Scholar
• KosticADXavierRJGeversDThe microbiome in inflammatory bowel disease: current status and the future aheadGastroenterology201414661489149924560869
   PubMed Web of Science ®Google Scholar
• RoglerGVavrickaSExposome in IBD: recent insights in environmental factors that influence the onset and course of IBDInflammatory Bowel Diseases201521240040825358064
   PubMed Web of Science ®Google Scholar
• SolbergICLygrenIJahnsenJClinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)Scand J Gastroenterol200944443144019101844
   PubMed Web of Science ®Google Scholar
• LangholzEMunkholmPDavidsenMNielsenOHBinderVChanges in extent of ulcerative colitis: a study on the course and prognostic factorsScand J Gastroenterol19963132602668833356
   PubMed Web of Science ®Google Scholar
• WatermanMKnightJDinaniAPredictors of Outcome in Ulcerative ColitisInflammatory Bowel Diseases20152192097210526177304
   PubMed Web of Science ®Google Scholar
• KissLSLakatosPLNatural history of ulcerative colitis: current knowledgeCurrent Drug Targets201112101390139521466488
   PubMed Web of Science ®Google Scholar
• SatsangiJSilverbergMSVermeireSColombelJFThe Montreal classification of inflammatory bowel disease: controversies, consensus, and implicationsGut200655674975316698746
   PubMed Web of Science ®Google Scholar
• LoftusEVJrClinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influencesGastroenterology200412661504151715168363
   PubMed Web of Science ®Google Scholar
• LoftusESilversteinMSandbornWTremaineWHarmsenWZinsmeisterAUlcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survivalGut200046333634310673294
   PubMed Web of Science ®Google Scholar
• MolodeckyNASoonISRabiDMIncreasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic reviewGastroenterology201214214654 e42 quiz e3022001864
   PubMed Web of Science ®Google Scholar
• GhoshSMitchellRImpact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) patient surveyJournal of Crohn’s & Colitis2007111020
   PubMed Web of Science ®Google Scholar
• IrvineEJQuality of life of patients with ulcerative colitis: past, present, and futureInflammatory Bowel Diseases200814455456517973299
   PubMed Web of Science ®Google Scholar
• FroslieKFJahnsenJMoumBAVatnMHGroupIMucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohortGastroenterology2007133241242217681162
   PubMed Web of Science ®Google Scholar
• GoodhandJRKamperidisNRaoAPrevalence and management of anemia in children, adolescents, and adults with inflammatory bowel diseaseInflammatory Bowel Diseases201218351351921604328
   PubMed Web of Science ®Google Scholar
• RutterMSaundersBWilkinsonKSeverity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitisGastroenterology2004126245145914762782
   PubMed Web of Science ®Google Scholar
• IrvingPMPasiKJRamptonDSThrombosis and Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology20053761762816206491
   PubMed Web of Science ®Google Scholar
• AndersenNNJessTRisk of cardiovascular disease in inflammatory bowel diseaseWorld J Gastrointest Pathophysiol20145335936525133036
   PubMedGoogle Scholar
• BassiADoddSWilliamsonPBodgerKCost of illness of inflammatory bowel disease in the UK: a single centre retrospective studyGut200453101471147815361497
   PubMed Web of Science ®Google Scholar
• KappelmanMDRifas-ShimanSLPorterCQDirect health care costs of Crohn’s disease and ulcerative colitis in US children and adultsGastroenterology200813561907191318854185
   PubMed Web of Science ®Google Scholar
• van der ValkMEMangenMJSeversMEvolution of costs of inflammatory bowel disease over two years of follow-upPLoS One2016114e014248127099937
   PubMed Web of Science ®Google Scholar
• EdwardsFCTrueloveSCThe course and prognosis of ulcerative colitisGut1963429931514084741
   PubMed Web of Science ®Google Scholar
• SutherlandLMacdonaldJKOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisThe Cochrane Database of Systematic Reviews20062Cd00054416625537
   PubMed Web of Science ®Google Scholar
• ArdizzoneSMaconiGRussoAImbesiVColomboEBianchi PorroGRandomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitisGut2006551475315972298
   PubMed Web of Science ®Google Scholar
• RutgeertsPSandbornWJFeaganBGInfliximab for induction and maintenance therapy for ulcerative colitisThe New England Journal of Medicine2005353232462247616339095
   PubMed Web of Science ®Google Scholar
• SandbornWJvan AsscheGReinischWAdalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitisGastroenterology20121422257265e25125322062358
   PubMed Web of Science ®Google Scholar
• LouisEIrvingPBeaugerieLUse of azathioprine in IBD: modern aspects of an old drugGut201463111695169924943205
   PubMed Web of Science ®Google Scholar
• FordACPeyrin-BirouletLOpportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trialsThe American Journal of Gastroenterology201310881268127623649185
   PubMed Web of Science ®Google Scholar
• DignassAEliakimRMagroFSecond European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosisJ Crohns Colitis201261096599023040452
   PubMed Web of Science ®Google Scholar
• JeuringSFBoursPHZeegersMPDisease outcome of ulcerative colitis in an Era of changing treatment strategies: results from the Dutch population-based IBDSL cohortJournal of Crohn’s & Colitis2015910837845
   PubMed Web of Science ®Google Scholar
• Vester-AndersenMKProsbergMVJessTDisease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapyThe American Journal of Gastroenterology2014109570571424642581
   PubMed Web of Science ®Google Scholar
• KaserAZeissigSBlumbergRSInflammatory bowel diseaseAnnual Review of immunology201028573621
   PubMed Web of Science ®Google Scholar
• SchulzOJaenssonEPerssonEKIntestinal CD103+, but not CX3CR1+, antigen sampling cells migrate in lymph and serve classical dendritic cell functionsThe Journal of Experimental Medicine2009206133101311420008524
   PubMed Web of Science ®Google Scholar
• MoraJRBonoMRManjunathNSelective imprinting of gut-homing T cells by Peyer’s patch dendritic cellsNature20034246944889312840763
   PubMed Web of Science ®Google Scholar
• BekiarisVPerssonEKAgaceWWIntestinal dendritic cells in the regulation of mucosal immunityImmunological Reviews201426018610124942684
   PubMed Web of Science ®Google Scholar
• SchweighofferTTanakaYTidswellMSelective expression of integrin alpha 4 beta 7 on a subset of human CD4+ memory T cells with Hallmarks of gut-trophismJournal of Immunology (Baltimore, Md : 1950)19931512717729
   Web of Science ®Google Scholar
• CaderMZKaserARecent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammationGut201362111653166424104886
   PubMed Web of Science ®Google Scholar
• McCarthyNEBashirZVossenkämperAProinflammatory Vδ2+ T cells populate the human intestinal Mucosa and enhance IFN-γ production by Colonic αβ T cellsThe Journal of Immunology201319152752276323904167
   PubMed Web of Science ®Google Scholar
• RottLSBriskinMJButcherECExpression of alpha4beta7 and E-selectin ligand by circulating memory B cells: implications for targeted trafficking to mucosal and systemic sitesJournal of Leukocyte Biology200068680781411129647
   PubMed Web of Science ®Google Scholar
• BergELMcEvoyLMBerlinCBargatzeRFButcherECL-selectin-mediated lymphocyte rolling on MAdCAM-1Nature199336664566956987505053
   PubMed Web of Science ®Google Scholar
• BriskinMWinsor-HinesDShyjanAHuman mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissueThe American Journal of Pathology19971511971109212736
   PubMed Web of Science ®Google Scholar
• BerlinCBergELBriskinMJα4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1Cell19937411851957687523
   PubMed Web of Science ®Google Scholar
• ArihiroSOhtaniHSuzukiMDifferential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn’s diseasePathology International2002525–636737412100519
   PubMed Web of Science ®Google Scholar
• HolzmannBWeissmanILPeyer’s patch-specific lymphocyte homing receptors consist of a VLA-4-like alpha chain associated with either of two integrin beta chains, one of which is novelThe EMBO Journal198986173517412670559
   PubMed Web of Science ®Google Scholar
• GhoshSGoldinEGordonFHNatalizumab for Active Crohn’s DiseaseNew England Journal of Medicine20033481243212510039
   PubMed Web of Science ®Google Scholar
• ChenC-HKularatnaGStoneCDGutierrezAMDassopoulosTClinical experience of natalizumab in Crohn’s disease patients in a restricted distribution programAnnals of gastroenterology2013263233238
   Google Scholar
• FedykERWyantTYangLLExclusive antagonism of the alpha4 beta7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primatesInflammatory Bowel Diseases201218112107211922419649
   PubMed Web of Science ®Google Scholar
• TrivediPJBrunsTWardSIntestinal CCL25 expression is increased in colitis and correlates with inflammatory activityJ Autoimmun2016689810426873648
   PubMed Web of Science ®Google Scholar
• WendtEKeshavSCCR9 antagonism: potential in the treatment of Inflammatory Bowel DiseaseClinical and Experimental Gastroenterology2015811913025897254
   PubMed Web of Science ®Google Scholar
• NguyenLPPanJDinhTTRole and species-specific expression of colon T cell homing receptor GPR15 in colitisNat Immunol201516220721325531831
   PubMed Web of Science ®Google Scholar
• ByrareddySNArthosJCicalaCSustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapyScience2016354630919720227738167
   PubMed Web of Science ®Google Scholar
• FeaganBGGreenbergGRWildGTreatment of Ulcerative Colitis with a Humanized Antibody to the α4β7 IntegrinNew England Journal of Medicine2005352242499250715958805
   PubMed Web of Science ®Google Scholar
• RosarioMDirksNLGastonguayMRPopulation pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s diseaseAlimentary Pharmacology & Therapeutics201542218820225996351
   PubMed Web of Science ®Google Scholar
• FasanmadeAAAdedokunOJFordJPopulation pharmacokinetic analysis of infliximab in patients with ulcerative colitisEur J Clin Pharmacol200965121211122819756557
   PubMed Web of Science ®Google Scholar
• ParikhALeachTWyantTVedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging studyInflammatory Bowel Diseases20121881470147922147460
   PubMed Web of Science ®Google Scholar
• FeaganBGRutgeertsPSandsBEVedolizumab as induction and maintenance therapy for ulcerative colitisNew England journal of Medicine2013369869971023964932
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGRutgeertsPVedolizumab as induction and maintenance therapy for Crohn’s diseaseNew England journal of Medicine2013369871172123964933
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJReinischWInfliximab, Azathioprine, or Combination Therapy for Crohn’s DiseaseNew England Journal of Medicine2010362151383139520393175
   PubMed Web of Science ®Google Scholar
• MainiRNBreedveldFCKaldenJRTherapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisArthritis and Rheumatism1998419155215639751087
   PubMed Web of Science ®Google Scholar
• EarpJFangLLianMAssessing labeling claims for drug interactions using a population PK approach: VedolizumabJournal of Pharmacokinetics and Pharmacodynamics2014411S39
   Google Scholar
• NeurathMFTravisSPMucosal healing in inflammatory bowel diseases: a systematic reviewGut201261111619163522842618
   PubMed Web of Science ®Google Scholar
• Pineton de ChambrunGPeyrin-BirouletLLemannMColombelJFClinical implications of mucosal healing for the management of IBDNature Reviews Gastroenterology & Hepatology201071152919949430
   PubMed Web of Science ®Google Scholar
• FeaganBGMcDonaldJGreenbergGAn ascending dose trial of humanized A4B7 antibody in ulcerative colitisGastroenterology20001184 Suppl 2A874
   Web of Science ®Google Scholar
• MosliMHMacDonaldJKBickstonSJVedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysisInflammatory Bowel Diseases20152151151115925844963
   PubMed Web of Science ®Google Scholar
• SalleronJDaneseSD’AgayLPeyrin-BirouletLEffectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological ChallengeJournal of Crohn’s & Colitis201610910961102
   Web of Science ®Google Scholar
• KeaneJGershonSWiseRPTuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agentThe New England Journal of Medicine2001345151098110411596589
   PubMed Web of Science ®Google Scholar
• ChristensenBGoeppingerSRColmanRPost-marketing experience of vedolizumab for IBD: The University of Chicago experienceJournal of Crohn’s & Colitis20159Suppl 1S388S389
   Google Scholar
• WalmsleyRSAyresRCPounderREAllanRNA simple clinical colitis activity indexGut199843129329771402
   PubMed Web of Science ®Google Scholar
• SheltonEAllegrettiJRStevensBEfficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter CohortInflammatory Bowel Diseases201521122879288526288002
   PubMed Web of Science ®Google Scholar
• VivioEEKanuriNGilbertsenJJVedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical PracticeJournal of Crohn’s & Colitis2016104402409
   PubMed Web of Science ®Google Scholar
• AmiotAGrimaudJCPeyrin-BirouletLEffectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology201614111593160126917043
   PubMed Web of Science ®Google Scholar
• BaumgartDCBokemeyerBDrabikAStallmachASchreiberSVedolizumab GermanyCVedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort studyAlimentary Pharmacology & Therapeutics201643101090110227038247
   PubMed Web of Science ®Google Scholar
• StallmachALangbeinCAtreyaRVedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational studyAlimentary pharmacology & therapeutics20164411–121199121227714831
   PubMed Web of Science ®Google Scholar
• SamaanMAPavlidisPJohnstonEVedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centresFrontline Gastroenterology2016 Published Online First: [10 Aug 2016]10.1136/flgastro-2016-100720
   Web of Science ®Google Scholar
• LinLLiuXWangDZhengCEfficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysisMedicine20159410e55625761174
   PubMed Web of Science ®Google Scholar
• DaneseSFiorinoGPeyrin-BirouletLBiological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysisAnnals of Internal Medicine20141601070471124842416
   PubMed Web of Science ®Google Scholar
• GrantAJLalorPFHubscherSGBriskinMAdamsDHMAd-CAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease)Hepatology20013351065107211343233
   PubMed Web of Science ®Google Scholar
• EksteenBHeatheringtonJOshiomoghoJIPanaccioneRKaplanGGhoshS812f efficacy and safety of induction dosing of Vedolizumab for reducing biliary inflammation in Primary Sclerosing Cholangitis (PSC) in individuals with inflammatory bowel diseaseGastroenterology1504S1268
   Web of Science ®Google Scholar
• LimTYPavlidisPPiraniTVedolizumab in inflammatory bowel disease associated with Autoimmune Liver Disease pre- and post-liver transplantation: a case seriesInflammatory Bowel Diseases20162210E39E4027556837
   PubMed Web of Science ®Google Scholar
• BloomgrenGRichmanSHotermansCRisk of natalizumab-associated progressive multifocal leukoencephalopathyNew England Journal of Medicine2012366201870188022591293
   PubMed Web of Science ®Google Scholar
• HaanstraKGHofmanSOLopes EstevaoDMAntagonizing the alpha4beta1 integrin, but not alpha4beta7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitisJournal of immunology2013190519611973
   PubMed Web of Science ®Google Scholar
• StuveOMarraCMJeromeKRImmune surveillance in multiple sclerosis patients treated with natalizumabAnnals of neurology200659574374716634029
   PubMed Web of Science ®Google Scholar
• WyantTLeachTSankohSVedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial resultsGut2015641778324763133
   PubMed Web of Science ®Google Scholar
• ColombelJFSandsBERutgeertsPThe safety of vedolizumab for ulcerative colitis and Crohn’s diseaseGut2016 Online First: [18 Feb 2016]10.1136/gutjnl-2015-311079
   Web of Science ®Google Scholar
• IrvineEJFeaganBRochonJQuality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study GroupGastroenterology199410622872968299896
   PubMed Web of Science ®Google Scholar
• FeaganBGPatelHColombelJFEffects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trialAlimentary pharmacology & therapeutics201745226427527859410
   PubMed Web of Science ®Google Scholar
• KaneSDixonLAdherence rates with infliximab therapy in Crohn’s diseaseAlimentary Pharmacology & Therapeutics20062471099110316984504
   PubMed Web of Science ®Google Scholar
• van der HaveMOldenburgBKapteinAANon-adherence to anti-TNF therapy is associated with illness perceptions and clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre studyJournal of Crohn’s & Colitis2016105549555
   PubMed Web of Science ®Google Scholar
• TewGWHackneyJAGibbonsDAssociation between response to Etrolizumab and expression of integrin alpha E and Granzyme A in colon biopsies of patients with ulcerative colitisGastroenterology2016150247748726522261
   PubMed Web of Science ®Google Scholar
• DuncanJCaulfieldSClarkAAndersonSSandersonJIrvingPPTH-071 A multidisciplinary virtual biologics clinic: is it worthwhile?Gut201559Suppl 1A151A152
   Google Scholar